Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Roof who wrote (707)	2/16/1998 4:36:00 PM
From: Keith J	Read Replies (1) of 1432

Jim, my understanding is that Hextend will compete with albumin, and for three reasons. One, Hextend safer in larger doses than hespan. Two, health/safety concerns with albumin. Three, Hextend will cost less than albumin. Also, others don't think the albumin market is that small. Crossen indicated about 1 million liters for hespan and 1 million liters for albumin used annually in the U.S. Just my 2 cents worth. KJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next